{"prompt": "['Appendix 36', 'EmiPref Patient Preference Questionnaire', '(United Kingdom/English)', '(Paper Version, United Kingdom/English)', 'Emicizumab - F. Hoffmann-La Roche Ltd', '67 / Protocol MO39129, Version 3']['SAMPLE INFORMED CONSENT FORMS', 'The sample Informed Consent Form and Assent Form have been revised to reflect the', 'changes to the protocol.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '68 / Protocol MO39129, Version 3']['TABLE OF CONTENTS', 'PROTOCOL AMENDMENT ACCEPTANCE FORM', '76', '1. BACKGROUND', '88', '1.1', 'Background on Hemophilia A with Inhibitors', '88', '1.2', 'Background on Emicizumab', '90', '1.2.1', 'Preclinical Experience', '90', '1.2.2', 'Clinical Experience', '92', '1.2.2.1', 'Studies ACE001JP and ACE002JP', '92', '1.2.2.2', 'JP29574', '93', '1.2.2.3', 'Studies BH29884 and BH29992', '93', '1.2.2.4', 'Pharmacokinetics', '98', '1.2.2.5', 'Anti-drug Antibodies', '98', '1.2.2.6', 'Peri-Operative Management of Patients on Emicizumab', '99', '1.3', 'Study Rationale and Benefit-Risk Assessment', '99', '2. OBJECTIVES AND ENDPOINTS', '100', '3. STUDY DESIGN', '101', '3.1', 'Description of the Study', '101', '3.2', 'End of Study and Length of Study', '103', '3.3', 'Rationale for Study Design', '104', '3.3.1', 'Rationale for Emicizumab Dose and Schedule', '104', '3.3.2', 'Rationale for Patient Population', '105', '3.3.3', 'Rationale for Control Group', '106', '3.3.4', 'Rationale for Biomarker Assessments', '106', '3.3.5', 'Rationale for Pharmacokinetic Sample Collection', 'Schedule', '107', '3.3.6', 'Rationale for Immunogenicity Sample Collection', '107', '3.3.7', 'Rationale for Disease Response-based Endpoints', '107', '3.3.8', 'Rationale for Primary Endpoint Selection', '107', '3.3.9', 'Rationale for Interim Analyses', '108', '3.3.10', 'Rationale for Patient-reported Outcome (PRO)', 'Assessments', '108', '4. MATERIALS AND METHODS', '109', '4.1', 'Patients', '109', 'Emicizumab - F. Hoffmann-La Roche Ltd', '69 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}